Icon expands U.S. and U.K. bioanalytical labs

Monday, September 10, 2012 09:48 AM

Icon, a global provider of outsourced development services, is expanding its U.S. and U.K. bioanalytical facilities to meet the growing demand for biomarker and cell-based assay services.

Icon has increased its bioanalytical laboratories in Whitesboro, N.Y., and Manchester, U.K., by 7,000 and 4,000 square feet, respectively. The expansions allow Icon to house dedicated immunoassay laboratories at each facility for biomarker testing and cell-based assays.

“We have expanded our bioanalytical facilities to provide the necessary scale to support the ever-broadening range of testing services required by our sponsors,” said Brian O’Dwyer, senior vice president of global bioanalytical services, development solutions, Icon. “In particular, the expansion of our dedicated biomarker testing laboratories allows us to support biomarker development programs across multiple testing platforms globally.”

Operating since 1988, Icon’s Whitesboro facility already features multiple wet laboratories and instrument laboratories for small and large molecules, including a specially designed hazardous lab for the analysis of HIV and hepatitis B infected samples. Similarly, Icon’s Manchester laboratory has provided bioanalytical support for both small and large molecule studies for almost 30 years and is located close to Icon 's hospital-based clinical pharmacology unit in Manchester.

Share:          
CWWeekly

January 19

Roche takes $1B majority stake in Foundation Medicine to use genomic testing to personalize oncology treatments

BRANY launches software, iPad app to streamline protocol creation for investigator-initiated trials

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January

All eyes on EMA’s adaptive licensing pilot
Sponsors could offer innovative drugs to patients 8 years sooner

Ice Bucket Challenge a boon for ALS research
Donations soar, but phenomenon difficult to replicate

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

December

Growing adoption of feasibility review committees
Early reports cite fewer amendments, improved cycle time

AMCs vying to better compete for industry trials
Working to conquer study start-up delays, IRB review process

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs